Protagonist Therapeutics, Inc. (NasdaqGM: PTGX)
Health Care · Biotechnology · US
$139.91
-0.72% today · +115.2% 1Y
Protagonist Therapeutics, Inc. (NasdaqGM: PTGX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $9.12B and employs 141 people.
Over the last twelve months the share price has gained 115.2%, trading between 62.24 and 160.81.
Tweenvest scores Protagonist Therapeutics, Inc. across four factors: quality 65/100, value 16/100, growth 62/100. Its strongest factor is quality.
PTGX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $9.12B
- Revenue (TTM)
- $281.99M
- P/E
- 115.40
- EPS
- 1.22
- Dividend yield
- —
- Beta (5Y)
- 1.52
- 52-week high
- $160.81
- 52-week low
- $62.24
- Avg volume (3M)
- —
- Shares outstanding
- 64.71M
- Employees
- 141
- Next earnings
- —
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
- ISIN
- US74366E1029
- Founded
- 2006
- Listed since
- Aug 11, 2016
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| ImmunityBio, Inc.NasdaqGS: IBRX | $10.33B | $9.91 | +1.64% |
| Vaxcyte, Inc.NasdaqGS: PCVX | $9.96B | $65.02 | -2.90% |
| Twist Bioscience CorporationNasdaqGS: TWST | $9.76B | $152.05 | -2.31% |
| Krystal Biotech, Inc.NasdaqGS: KRYS | $9.61B | $327.30 | +0.84% |
| Kymera Therapeutics, Inc.NasdaqGM: KYMR | $8.93B | $109.30 | +1.78% |
| Arrowhead Pharmaceuticals, Inc.NasdaqGS: ARWR | $8.68B | $60.74 | -1.20% |
| Cytokinetics, IncorporatedNasdaqGS: CYTK | $8.50B | $62.01 | +1.46% |
| Praxis Precision Medicines, Inc.NasdaqGS: PRAX | $8.25B | $263.55 | -10.82% |
Figures last refreshed Oct 4, 2026.